Curated News
By: NewsRamp Editorial Staff
March 17, 2026

Scinai Immunotherapeutics Faces Nasdaq Compliance Challenge

Discuss on LinkedIn Discuss on Substack Discuss on Telegram
Original Source

TLDR

  • Scinai Immunotherapeutics faces a potential delisting risk, offering investors a chance to assess turnaround potential or short-selling opportunities before the September 2026 deadline.
  • Scinai Immunotherapeutics received a Nasdaq non-compliance notice on March 12, 2026, for trading below $1.00 for 30 days, with a 180-day grace period to regain compliance.
  • Despite regulatory challenges, Scinai continues developing innovative immunology therapies that could improve patient outcomes and advance medical science for autoimmune and inflammatory diseases.
  • Scinai Immunotherapeutics, a biopharmaceutical company developing licensed therapies, now has until September 2026 to boost its stock price above $1.00 to maintain Nasdaq listing.

Impact - Why it Matters

This news matters because it highlights the financial and regulatory pressures facing publicly traded biotech companies. For investors, a potential delisting from Nasdaq could significantly impact liquidity, stock visibility, and investor confidence, potentially making it harder to raise capital for critical research. Scinai's situation reflects broader market challenges where early-stage biopharma firms, despite promising science, can struggle with stock valuation. The company's dual focus on internal drug development and external CDMO services means its financial health directly affects not only its own pipeline—including therapies licensed from respected entities like the Max Planck Society—but also the projects of its client companies. The 180-day compliance period offers a window for recovery, but failure could lead to relegation to over-the-counter markets, often associated with higher volatility and lower prestige, which might hinder partnerships and growth. This underscores the delicate balance between scientific innovation and market sustainability in the high-stakes biotech sector.

Summary

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), a biopharmaceutical company developing innovative immunology therapies, has received a critical notification from the Nasdaq Listing Qualifications Department. The company was informed on March 12, 2026, that it is no longer in compliance with the Nasdaq Capital Market's minimum bid price requirement, specifically Listing Rule 5550(a)(2). This non-compliance stems from the company's American Depositary Shares (ADSs) trading below the $1.00 threshold for 30 consecutive business days, a situation that can trigger delisting procedures. However, the notice does not have an immediate effect on the listing or trading of Scinai's shares on the exchange.

The company has been granted a 180-day grace period, extending through September 8, 2026, to rectify the situation. To regain compliance, Scinai's closing bid price must meet or exceed $1.00 for a minimum of 10 consecutive business days within this timeframe. This development places the spotlight on the company's stock performance and its ability to meet exchange standards. Scinai's business model is twofold: it advances a pipeline of therapeutic candidates licensed from prestigious institutions like the Max Planck Society and PinCell S.r.l., and it operates Scinai Biopharma Services Ltd., a contract development and manufacturing organization (CDMO) that provides essential services to other biotechnology and pharmaceutical firms.

The news release was distributed via InvestorWire, a specialized communications platform that is part of the broader IBN (InvestorBrandNetwork) ecosystem. This platform offers advanced wire-grade press release syndication and is one of over 75 brands within the Dynamic Brand Portfolio at IBN. For investors seeking more details, the full press release is available, and the latest news and updates relating to SCNI can be found in the company's dedicated newsroom. This situation is a pivotal moment for Scinai Immunotherapeutics as it navigates regulatory requirements while continuing its mission in the competitive biopharmaceutical landscape.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Scinai Immunotherapeutics Faces Nasdaq Compliance Challenge

blockchain registration record for this content.